ImmunSYS, Inc. is a clinical-stage biopharmaceutical company focused on the development of breakthrough cancer immunotherapy products for patients with metastatic solid tumors, with initial focus on the clinical advancement of its proprietary platform technology, YourVaccx TM for the treatment of metastatic prostate cancer. Data from a Proof of Concept (PoC) study for YourVaccx demonstrated a 50% complete response rate , (near or complete remission) with durable responses now exceeding 5 years.
PoC clinical data also demonstrated early positive signals in other metastatic sold tumor cancers including pancreatic cancer. The YourVaccx therapy is provided in an outpatient setting and is generally well tolerated by the patients. ImmunSYS is committed to developing potentially transformative therapies for patients with metastatic cancer.
Radio Broadcast Feature
Begin listening at 1:05 in the podcast.
Get access to the important information you need from Farmers for Innovation. Using the fields below, please provide your information so that we may reach out regarding next steps and access to the FFI Data Room.